A Neato Cell: Data Show Favorable Efficacy, Toxicity For Arcellx/Gilead Myeloma CAR-T

 
• By Alaric DeArment
  
Gilead's Kite Pharma is partnered with Arcellx on the development of anito-cel, also known as CART-ddBCMA • Source: Scrip
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D